Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.65 |
| ▸ | MGLL | Q99685 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306551 | 0.94 | ALDH1A1 (0.64) | CA1CA2MGLLRAB9AMEN1 | |
| SCHEMBL197633 | 0.85 | RAB9A (0.82) | CA1CA2RAB9AMEN1LMNA | |
| SCHEMBL13019488 | 0.85 | RAB9A (0.82) | CA1CA2RAB9AMEN1LMNA | |
| SCHEMBL23154639 | 0.84 | MGLL (0.70) | CA1CA2MGLLRAB9AMEN1 | |
| SCHEMBL28945381 | 0.83 | ALDH1A1 (0.50) | CA1CA2MGLLRAB9ATRPV1 | |
| SCHEMBL13534566 | 0.83 | RAB9A (0.78) | CA1CA2RAB9AMEN1LMNA | |
| Benzophenone SCHEMBL28231198 | 0.83 | RAB9A (0.78) | CA1CA2RAB9AMEN1LMNA | |
| SCHEMBL28246134 | 0.83 | RAB9A (0.78) | CA1CA2RAB9AMEN1LMNA | |
| SCHEMBL41657 | 0.83 | RAB9A (0.78) | CA1CA2RAB9AMEN1LMNA | |
| SCHEMBL29143580 | 0.83 | RAB9A (0.78) | CA1CA2RAB9AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1019414-B1 | PROCESS FOR PREPARING ORGANIC BORONIC ACID DERIVATIVES USING DIBORONIC ACID | COMMW SCIENT IND RES ORG (AU) | 2005-06-08 | — | — | EP | claimed |
| US-20030220520-A1 | Process for preparing organic boronic acid derivatives using diboronic acid | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2003-11-27 | — | — | US | claimed |
| US-6603004-B2 | Reacting diboron tetrahydroxide with boronic acid derivatives in presence of group 8-11 metal catalyst; one pot; no need for hydrolysis or hydrogenolysis | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2003-08-05 | — | — | US | claimed |
| US-20020151743-A1 | Process for preparing organic boronic avid derivatives using diboronic acid | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2002-10-17 | — | — | US | claimed |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | disclosed |
| US-9108989-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108989-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140121183-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121183-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8629125-B2 | Inhibitors of fatty acid amide hydrolase | Infinty Pharmaceuticals, Inc. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629125-B2 | Inhibitors of fatty acid amide hydrolase | Infinty Pharmaceuticals, Inc. (US) | 2014-01-14 | — | — | US | disclosed |
| US-7947663-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-7122699-B2 | Process for preparing organic boronic acid derivatives using diboronic acid | BORON MOLECULAR LIMITED (AU) | 2006-10-17 | — | — | US | disclosed |
| EP-1019414-B1 | PROCESS FOR PREPARING ORGANIC BORONIC ACID DERIVATIVES USING DIBORONIC ACID | COMMW SCIENT IND RES ORG (AU) | 2005-06-08 | — | — | EP | disclosed |
| US-6603004-B2 | Reacting diboron tetrahydroxide with boronic acid derivatives in presence of group 8-11 metal catalyst; one pot; no need for hydrolysis or hydrogenolysis | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2003-08-05 | — | — | US | disclosed |
| US-6448433-B1 | REACTING AN ORGANIC HALIDE WITH TETRAHYDROXYDIBORON; GROUP 8-11 METAL CATALYST | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) | 2002-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220520-A1 | Process for preparing organic boronic acid derivatives using diboronic acid | BTD, BRAP, DBF4 | CA1 851/4885CA2 302/4885MGLL 3479/4885 |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | CA1 908/4885CA2 1331/4885MGLL 15/4885 |
| US-20020151743-A1 | Process for preparing organic boronic avid derivatives using diboronic acid | BTD, BRAP, BCL6B | CA1 1108/4885CA2 372/4885MGLL 3551/4885 |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | FAAH, FAAH2, ASAH1 | CA1 821/4885CA2 1188/4885MGLL 17/4885 |
| US-20140121183-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | CA1 908/4885CA2 1331/4885MGLL 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.